



Anti-cancer Activity of *Garcinia mangostana* L. and Its Derivatives in Cervical Cancer

S. V. Kirthanashri¹, N. Ramesh Kumar² and S. Chitra^{3*}

¹Amity Institute of Molecular Medicine and Stem Cell Research, Amity University, Sector - 125, Gautam Buddha Nagar Noida - 201313, Uttar Pradesh, India.

²Department of Pharmaceutical Chemistry, C. L. Baid Metha College of Pharmacy, Thorapakkam, Chennai-600097, India.

³Captain Srinivasa Murthy Regional Ayurveda Drug Development Institute, Central Council for Research in Ayurvedic Sciences, M/o AYUSH Govt. of India, A. A. Hospital Campus, Arumbakkam, Chennai-600106, India.

Authors' contributions

This work was carried out in collaboration among all authors. Author SVK performed the laboratory analyses and statistics. Author NRK managed the literature searches. Author SC designed the study, wrote the protocol and draft of the manuscript. All authors read and approved the final manuscript.

Article Information

DOI: 10.9734/AJRB/2020/v6i430125

Editor(s):

(1) Dr. Asmaa Fathi Moustafa Hamouda, Jazan University, Saudi Arabia.

Reviewers:

(1) D. Malathy, Vels Institute of Science, Technology & Advanced Studies (VISTAS), India.

(2) Inès Karmous, University of Gabes, Tunisia.

(3) Marco Túlio Alves da Silva, São Paulo College, Brazil.

Complete Peer review History: <http://www.sdiarticle4.com/review-history/57931>

Original Research Article

Received 20 April 2020

Accepted 25 June 2020

Published 03 July 2020

ABSTRACT

The *Garcinia mangostana* Linn, a medicinal plant commonly used in Southeast Asia. The crude extract and isolated metabolites were used to evaluate its potential anti-cancer activity which was compared to methotrexate (MTX) in cervical cancer cell line. The present study involved in using crude mangosteen (CM), γ -mangostin (γ -M), isopropyl mangostin (IPM) and Di-O-methyl mangostin (DMM) against the standard anti-neoplastic drug MTX. Cell viability and cytotoxicity by lactate dehydrogenase (LDH) were assessed. Analysis of DNA fragmentation and clonogenic assay further supports the anti-cancer activity of the drugs in *HeLa* cells. The IC₅₀ value for CM, γ -M, DMM, IPM and MTX were 13.4 μ g, 34.84 μ M, 15.57 μ M 5.3 μ M and 16.05 μ M respectively observed in the present study. This study suggests that the *G. mangostana* and its derivatives have potential anti-cancer activity an *in vitro* study in cervical cancer.

*Corresponding author: E-mail: Chires2006@gmail.com;

Keywords: Cervical cancer; *Garcinia mangostana*; DNA fragmentation; MTT; clonogenic assay; cytotoxicity.

1. INTRODUCTION

Squamous cell carcinoma (SCC) is a second most common cancer of skin, lips, mouth, prostate, urinary bladder, cervix, esophagus and vagina. The ratio of SCC in male to female is 2:1, also estimated that there are approximately 7.6 million or 13% of the world population of mortality due to cancer and the cancer risk may exceed about 26 million populations and 17 million will die of from cancer in 2030 if it is not controlled [1]. Cervical cancer is the second most common cancer among Indian women. In India new cases of cervical cancer detected are 96,922 and deaths 60,078 every year. Chemotherapeutic drugs are often used in combination with an either radiotherapy or surgery or both. The treatment side effect includes nausea, vomiting, diarrhea, hair loss, leucopenia etc. [2]. The incidence increases with age and other socio-demographic factors includes virus, diet, alcohol, tobacco, occupational hazard, sunlight etc. are also contributed to the development of SCC of cervix. Human cancer cell lines are fundamental models, either *in vitro* as monolayer culture or *in vivo* as xenograft in mice, to study the efficacy of therapeutic agents in cancer therapy. *HeLa* was the first cultured cancer cell line, which was derived from cervical cancer cells taken from Henrietta Lacks in 1951 [3]. Since then, several cervical cancer cell lines including SiHa, CaSki, C-33A and ME-180 were established [4]. It is worth to mention that these cell lines do not have equal value as tumor models, the *in vitro* results of drug efficacy experiments are different. For decades, human immortal cancer cell lines have constituted an accessible, easily usable set of biological models with which to investigate cancer treatment and to explore the potential efficacy of anti-cancer drug research. *HeLa* cell line is a suitable cell line model to study cervical cancer *in vitro*. Human papilloma virus (HPVs) is frequently integrated into the cellular DNA in cervical cancers [5] and the two strains of HPV together are responsible for approximately 70% of all cervical cancers [6].

Studies on natural compounds from fruits and vegetables for their health-promoting effects in recent years have received a great attention due to their diverse source of Phytochemicals and daily consumption of fruits and vegetables has been shown to lower the risk of some chronic

non-communicable diseases like cardiovascular illness and cancers [7]. Dietary phytochemicals play a vital role in cancer prevention and it is estimated that more than 5000 phytochemicals have been identified to have an anti-proliferative activity [8,9]. In this context, evidence-based molecules for cancer prevention are very well mandatory for practical use. Among them, polyphenols are of great attention as chemopreventive agents because of their anti-oxidative and possible anti-cancer activities [10, 11]. Mangosteen is a tropical fruit from *Garcinia mangostana* L., family of Guttiferae that grow in hot and humid climates. The alternative names are mangostan, manggis, mangis, mang etc. Mangosteen has a source of xanthenes, mangostin, tannin, chrysanthemine, gartanin, garcinone, vitamin B1, B2 and vitamin C. Xanthenes are rich in mangosteen and its derivatives such as α , β and γ -mangostin have superior biological activity [12]. All parts of the mangosteen can be used in the treatment of various ailments and phytochemical compounds such as oxygenate and a prenylated xanthenes are rich in mangosteen than other plants was reported [13]. It was stated to have anti-inflammatory [14], anti-microbial [15], anti-cancer [16], anti-angiogenic [17] and *in vitro* anti-oxidant [18] activities. Xanthenes from mangosteen showed multi-targeting pharmacological properties were studied [19]. Cancer represents a public health problem worldwide and the development of new drug molecules are still an urgent need. We previously investigated an anti-proliferative activity of xanthenes from *G. mangostana* in human breast cancer and laryngeal carcinoma cell lines, interestingly, γ -mangostin induced mitochondrial dysfunction, cell-cycle arrest and apoptosis in MCF7 and Hep2 cell lines [20]. In this paper, we discussed the mechanism of anti-cancer effect of CM and its derivatives from *G. mangostana* and its possible chemo preventive activity in cervical cancer.

2. MATERIALS AND METHODS

2.1 Cell Culture

The human cervical cancer cell line, *HeLa* was obtained from National Centre for Cell Science (NCCS), Pune, India. Cells were routinely maintained in Dulbecco's Modified Eagle's Medium (DMEM) with 10% fetal bovine serum

(Gibco) and incubated at 37°C under 5% CO₂ at high humidity. Inhibitory concentration (IC₅₀) was done by the method of Kuo et al. [21]. Briefly, 48-hour monolayer culture of *HeLa* cells at a concentration of 1x10⁴ cells/well was seeded in 96-well microtiter plate. Different concentrations of CM, γ-M, IPM, DMM and standard anti-neoplastic drug, MTX were mixed in dimethyl sulfoxide (DMSO) and added to the cells. These were incubated at 37°C under 5% CO₂ to derive IC₅₀ concentration of the drugs.

2.2 Experimental Design

Study design comprised of six groups; group 1: *HeLa* cells; group 2: *HeLa* cells treated with CM; group 3: *HeLa* cells treated with γ-M; group 4: *HeLa* cells treated with IPM; group 5: *HeLa* cells treated with DMM and group 6: *HeLa* cells treated with MTX.

2.3 Trypan Blue Exclusion Assay

Trypan blue exclusion assay was performed by the standard method of Altman et al. [22]. Briefly, 48-hour monolayer culture of cancer cells at a concentration of 1x10⁴ cells/well was seeded in 96-well microtitre plate. Added suitable IC₅₀ concentrations of drugs and cells were supplied with 2% DMEM, and incubated at 37°C under 5% CO₂ for 24 hours.

2.4 Cell Viability Assay

Cell viability was estimated using 3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT; Sigma- Aldrich, Louis, MO, USA) according to the standard method [23]. This method is based on the reduction of a tetrazolium salt by mitochondrial dehydrogenase enzyme in viable cells. Culture medium was removed after a predetermined time; cells were incubated with 0.2 mL of MTT (5mg/mL) for 3 hours at 37°C. After incubation, the medium was aspirated and the formazan reaction product was dissolved in suitable solvent and measured at 545 nm. The results are expressed as percentage viability.

2.5 Evaluation of Cytotoxicity

Cytotoxicity was assayed through LDH release. In order to evaluate the cytotoxic effects of CM and its derivatives, cells at a density of 2 x10⁴/cm² were plated in 24-well cell culture plate in DMEM medium containing 10% FBS and incubated at 37°C. After suitable time of

incubation, supernatants and cell suspension were used for LDH release by standard procedure [24].

2.6 DNA Fragmentation and Clonogenic Assay

The DNA Fragmentation assay was performed by the standard method using agarose gel electrophoresis [25,26]. The clonogenic assay was done based on the standard protocol [27]. This assay is based on the ability of a single cell to grow into a colony. Briefly, 1% agar with 20% FBS was used as a base and 0.7% agarose with 10% FBS along with 2000 cells/plate/0.1mL to top layer. Plates were incubated for 14 days in a CO₂ incubator; colonies were fixed with glutaraldehyde (6.0% v/v), stained with crystal violet (0.5% w/v) and counted using a stereomicroscope.

$$\text{Calculation} = \frac{\text{Number of clones in treated wells}}{\text{Number of clones in control wells}} \times 100$$

2.7 Statistical Analysis

Statistical analysis was done using ANOVA. p<0.05 was considered as statistically significant.

3. RESULTS

IC₅₀ for crude mangosteen and its derivatives was shown in Fig. 1. The IC₅₀ for CM, γ-M IPM, DMM and MTX were 13.4μg, 5.30μM, 34.84μM, 15.57μM and 16.05μM were obtained for the present study.

Fig. 2 shows the IC₅₀ analysis for CM and its derivatives with solvent DMSO. There was no significant change in cell number for DMSO treated group in the present study. DMSO is a standard solvent used to dissolve the drugs in cell culture studies. Trypan blue exclusion assay for CM and its derivatives are shown in Fig. 3. The cell number was decreased significantly (p<0.001) in group 2 to 6 when compared to group 1. Cell viability was evaluated through MTT assay and it is shown in Fig. 4. Considering 100% viability in group 1, the drug treated groups showed significant decrease in group 2, 4 & 5 (p<0.05) and group 3 & 6 (p<0.01).

The LDH activity in cell suspension and cell supernatant is given in Fig. 5. The cancer cell itself produce cytotoxicity, this was observed in the present study. The LDH level was significantly increased in group 2 to 5 (p<0.01)

and group 6 ($p < 0.05$) when compared to group 1. The LDH level in cell supernatant was significantly decreased in group 2 to 5 ($p < 0.01$) and group 6 ($p < 0.05$) when compared to group 1.

The results of DNA fragmentation was shown in Fig. 6. DNA fragmentation was observed in group 2 to 5 whereas group 6 did not show any DNA fragmentation.




Fig. 1. IC₅₀ analysis




Fig. 2. IC₅₀ analysis of CM and its derivatives




Fig. 3. Trypan blue exclusion assay

Gp 1- HeLa cells; Gp 2- HeLa cells + CM; Gp 3- HeLa cells + γ -M; Gp 4- HeLa cells + IPM; Gp 5- HeLa cells + DMM; Gp 6- HeLa cells + MTX; *** $p < 0.001$

Clonogenic assay was depicted in Fig. 7. This is one of the important confirmatory tests used to study the anti-cancer efficacy of the drugs. Morphologies and viabilities of migratory abilities of *HeLa* cells were analyzed using this assay. Studied the percentage control

of cell growth as a colonies formed from day 7 to day 14. The present study showed that the growth control of 79% for CM, 97.6% for γ -M, 88.0% for IPM, 89.4% for DMM and 91.3% for MTX for 14th day when compared to 7th day.




Fig. 4. Cell viability assay

Gp 1- *HeLa* cells; Gp 2- *HeLa* cells + CM; Gp 3- *HeLa* cells + γ -M; Gp 4- *HeLa* cells + IPM; Gp 5- *HeLa* cells + DMM; Gp 6- *HeLa* cells + MTX; * $p < 0.05$; ** $p < 0.01$




Fig. 5. Cell cytotoxicity assay

Gp 1- *HeLa* cells; Gp 2- *HeLa* cells + CM; Gp 3- *HeLa* cells + γ -M; Gp 4- *HeLa* cells + IPM; Gp 5- *HeLa* cells + DMM; Gp 6- *HeLa* cells + MTX; * $p < 0.05$; ** $p < 0.01$




Fig. 6. DNA fragmentation assay

Lane 1- *HeLa* cells; Lane 2- *HeLa* cells + CM; Lane 3- *HeLa* cells + γ -M; Lane 4- *HeLa* cells + IPM; Lane 5- *HeLa* cells + DMM; Lane 6- *HeLa* cells + MTX; Lane 7- Marker




Fig. 7. Clonogenic assay

Gp 1- HeLa cells; Gp 2- HeLa cells + CM; Gp 3- HeLa cells + γ -M; Gp 4- HeLa cells + IPM; Gp 5- HeLa cells + DMM; Gp 6- HeLa cells + MTX; A-7th day; B-14th day; C-% Growth control between 7th & 14th day

4. DISCUSSION

The prenylated xanthenes from the pericarps of mangosteen were examined for the effect on the growth of human cervical cancer cells. Trypan blue stains dead cells and live cells appear translucent depending on plasma membrane integrity and permeability. The trypan blue exclusion assay showed that 66.92%, 79.04%, 68.43%, 55.81% and 58.33% for CM, γ -M, IPM, DMM and MTX were respectively when compared to untreated cancer cells. Several lines of evidence from numerous *in vitro* and *in vivo* studies have confirmed that xanthenes inhibit proliferation of a wide range of human tumor cell types by modulating various targets and signal transduction pathways. Cancer prevention using non-toxic chemical entities, generally known as “chemoprevention” is a more pragmatic and primary step for the management of malignant diseases. Due to limitations of existing therapies, natural products may serve as chemoprevention regimen and/or novel adjunctive agents to fill a significant need in the effective, safe, and less invasive treatment of cancer. IPM derivative of the present study showed a superior and potent inhibitory activity, this might be due to the presence of more number of hydroxyl groups in its structure. The percentage viability was done using MTT assay considering 100% for group 1, the other groups showed that 71%, 54%, 69%, 70% and 60% for CM, γ -M, IPM, DMM and MTX respectively. The percentage control in cell growth was higher for γ -M followed by MTX, IPM, DMM and CM in the present study. In addition, xanthenes especially γ -M could inhibit cell growth via decreasing aromatase activity which is required for the growth of estrogen-dependent breast cancer

[28]. As a whole the anti-tumor activity of xanthenes from *G. mangostana* includes suppression of tumor cell proliferation, cell-cycle arrest, induction of apoptosis and differentiation, reduction in inflammation, inhibition of adhesion, invasion and metastasis [29-31]. A reduction in cell number in MTX treated groups of present study might be due to inhibition of DNA synthesis, either by blocking the formation of pyrimidine nucleotides via reduction of folate reductase enzyme or inhibiting the formation of tetrahydrofolate.

Cell cytotoxicity was observed through LDH release and it is a stable cytoplasmic enzyme present in all cells and rapidly released into the cell supernatant upon damage of the plasma membrane. Therefore, the release of LDH from cells leads to reduced levels in cell suspension of all drug treated groups whereas in cell supernatant the levels were increased. This change may be due to mangosteen and its derivatives control most of the enzymes involved in the regulatory mechanism of cancer [32-34]. The prenyl group of mangosteen is considered to be implicated in the internalization into the cell, which in turn leads to interaction with the signal transduction molecules and the proteins involved in mitochondrial permeability transition [35,36] which was evident in CM and its derivative treated groups of the present study. Studies revealed that, xanthenes not only inhibit the proliferation of tumor cells but also induces cell death through activation of caspase cascade in *in vitro* [37]. The cytotoxicity of MTX results from three important actions: inhibition of dihydroxy folate reductase (DHFR), inhibition of thymidylate synthase, and alteration of the transport of reduced folates. The affinity of DHFR to MTX is

far greater than its affinity for folic acid or dihydrofolic acid.

Apoptosis is an innate mechanism of eukaryotic cell suicide, which plays a major role in many physiological and pathological processes. During apoptosis, a series of reorganization occurs in the cell: chromatin condensation, loss of cell volume and membrane blebbing is some of the most evident morphological changes of apoptotic cells. Responsible for DNA cleavage is believed to be an endogenous Ca^{2+} and Mg^{2+} -dependent endonuclease able to break double stranded DNA at inter nucleosomal sites [38]. Therefore, apoptotic DNA cleavage results in characteristic fragments of oligonucleosomal size (>500 bp). The typical ladder pattern of DNA fragmentation was observed in the present study for CM and its derivatives. No DNA fragmentation was noticed in MTX treated group which indicates that MTX is an anti-metabolite which controls cell proliferation through folate reductase pathway not through apoptotic pathway which was evident in the present study. Several studies have showed that clonogenic assay may be carried out 1 to 3 weeks. In our present study, the confluent colonies were found upto two weeks, therefore, the percentage cell growth control in the form of colonies formed between day 7 to day 14 which showed that $97.6 < 91.3 < 89.4 < 88.0 < 79.0$ for $\gamma\text{-M} < \text{MTX} < \text{IPM} < \text{DMM} < \text{CM}$ respectively. MTX competitively inhibits dihydrofolate reductase, an enzyme that participates in the tetrahydrofolate synthesis. MTX is still used in the treatment of a variety of tumors, including acute lymphocytic leukemia [39], breast cancer [40], osteosarcoma [41], primary central nervous system lymphoma [42] and head and neck cancer [43]. This metabolic step is essential for de novo synthesis of thymidine nucleotides for DNA synthesis. DHFR was the first enzyme to be identified as a cellular target for the antifolates aminopterin and MTX [44]. The latter exhibits its anti-cancer effect by almost irreversible inhibition of DHFR, with subsequent disruption of purine and pyrimidine synthesis [45]. MTX can induce apoptosis through both mitochondrial pathway and p53 dependent pathway. Another major pathway for the induction of apoptosis is the mitochondrial pathway or the intrinsic pathway [46]. The anti-cancer mechanism of MTX acts through initiation of p53-dependent apoptosis. MTX can induce p53 acetylation at Lys373/Lys382 and phosphorylation at Ser15/Ser392 [47]. From the above literature, the MTX acts as both p53 and DHFR pathway. Therefore MTX was selected for this study to evaluate its anti-cancer activity.

Hence the present study showed that $\gamma\text{-M}$ has superior anti-cancer activity followed by IPM than CM. Therefore further studies are required to evaluate anti-cancer activity of xanthenes from mangosteen and MTX with caspase mediated pathway such as both intrinsic and extrinsic in cervical cancer cell lines might help to understand the exact mechanism behind these drugs.

5. CONCLUSION

G. mangostana have become very popular fruit and dietary supplement and they are the rich source of various remarkable natural compounds of xanthenes with multi-targeting biological properties like anti-oxidant, anti-cancer, anti-ulcer anti-microbial and anti-inflammatory activities. Some xanthenes were synthesized and modified by several techniques to create novel compounds that may improve the efficacy. However, the relation between mangosteen and its derivatives has not been extensively studied in cancer. Further research is needed to study on the exact mechanisms of action and this can be extrapolated to new drug discoveries. Increasing awareness on the utilization of this fruit for public benefits is highly encouraged. Proteomic and genomic studies are needed to determine the efficacy of this fruit extract to serve as natural anti-cancer agent in treatment of cancer.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

1. Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture. *Eur J Cancer*. 2001;37(Suppl 8): S4–S66.
2. Kayl AE, Meyers CA. Side-effects of chemotherapy and quality of life in ovarian and breast cancer patients. *Curr Opin Obstet Gynecol*. 2006;18:24–8.
3. Lucey BP, Nelson-Rees WA, Hutchins GM. Henrietta lacks, HeLa cells and cell culture contamination. *Arch Pathol Lab Med*. 2009;133(9):1463–7.
4. Gillet JP, Varma S, Gottesman MM. The clinical relevance of cancer cell lines. *JNCI J. Nat. Cancer Inst*. 2013;105:452–8.
5. Burd EM. Clin human papillomavirus and cervical cancer. *Microbiol Rev*. 2003;16(1): 1–17.

6. Lowy DR, Solomon D, Hildesheim A, Schiller JT, Schiffman M. Human papillomavirus infection and the primary and secondary prevention of cervical cancer. *Cancer*. 2008;113:1980–93.
7. Boeing H, Bechthold A, Bub A, Ellinger S, Haller D, Kroke A, et al., Critical review: Vegetables and fruit in the prevention of chronic diseases. *Eur J Nutr*. 2012;51(6):637–63.
8. Li W, Guo Y, Zhang C, Wu R, Yang AY, Gaspar J, et al. Dietary phytochemicals and cancer chemoprevention: A perspective on oxidative stress, inflammation and epigenetics. *Chem Res Toxicol*. 2016;29(12):2071–95.
9. Meybodi NM, Mortazavian AM, Monfared AB, Sohravandi S, Meybodi FA. Phytochemicals in cancer prevention: A review of the evidence, *Int J Cancer Manag*. 2017;10(1):e7219.
10. Venugopal R, Liu RH. Phytochemicals in diets for breast cancer prevention: The importance of resveratrol and ursolic acid. *Food Sci Human Wellness*. 2012;1:1–13.
11. Günthera S, Ruhe C, Derikito MG, Bose G, Sauer H, Wartenberg M. Polyphenols prevent cell shedding from mouse mammary cancer spheroids and inhibit cancer cell invasion in confrontation cultures derived from embryonic stem cells. *Cancer Lett*. 2007;250:25-35.
12. Shan T, Ma Q, Guo K, Liu J, Li W, Wang F, Wu E. Xanthones from mangosteen extracts as natural chemopreventive agents: potential anti-cancer drugs. *Curr Mol Med*. 2011;11(8):666–77.
13. Govindachari T, Kalyanaraman P, Muthukumaraswamy N, Pai B. Xanthones of *Garcinia mangostana* Linn. *Tetrahedron*. 1971;27:3919-26.
14. Bumrungpert A, Kalpravidh RW, Chuang CC, Overman A, Martinez K, Kennedy A, et al. Xanthones from mangosteen inhibit inflammation in human macrophages and in human adipocytes exposed to macrophage-conditioned media. *J Nutr*. 2010;140:842–7.
15. Anggia V, Bakhtiar A, Arbain D. The isolation of xanthones from trunk latex of *Garcinia mangostana* linn. And their anti-microbial activities. *Indo J Chem*. 2015;15: 187-93.
16. Kumazaki M, Shinohara H, Taniguchi K, Ueda H, Nishi M, Ryo A, et al. Understanding of tolerance in TRAIL-induced apoptosis and cancelation of its machinery by alpha-mangostin, a xanthone derivative. *Oncotarget*. 2015;6:25828–42.
17. Jittiporn K, Suwanpradid J, Patel C, Rojas M, Thirawarapan S, Moongkarndi P, et al. Anti-angiogenic actions of the mangosteen polyphenolic xanthone derivative alpha-mangostin. *Microvasc Res*. 2014;93:72–9.
18. Jung HA, Su BN, Keller WJ, Mehta RG, Kinghorn AD. Antioxidant xanthones from the pericarp of *Garcinia mangostana* (Mangosteen). *J Agric Food Chem*. 2006; 54:2077–82.
19. Jindarat S. Xanthones from mangosteen (*Garcinia mangostana*): Multi-targeting pharmacological properties. *J Med Assoc Thai*. 2014;97:S196–201.
20. Chitra S, Krithika MV, Pavithra S. Induction of apoptosis by xanthones from *Garcinia mangostana* Linn. in human breast and laryngeal carcinoma cell lines. *Int. J Pharma and Biosci*. 2010;1(3):1-8
21. Kuo CC, Wang SP, Wentworth BB, Grayston JT. Primary isolation of TRIC organisms in *HeLa* 229 cells treated with DEAE-dextran. *J Infect Dis*. 1972;125: 665-8.
22. Altman SA, Randers L, Rao G. Comparison of trypan blue dye exclusion and fluorometric assays for mammalian cell viability determinations. *Biotech Progress*. 1993;9(6):671-4.
23. Tim M. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. *J Immunol Methods*. 1983;65(1-2):56-63.
24. Chan FK, Moriwaki K, De Rosa MJ. Detection of necrosis by release of lactate dehydrogenase activity. *Immune Homeostasis: Meth Protoc*. 2013;65-70.
25. Kasibhatla S, Mendes GPA, Finucane D, Brunner T, Wetzel EB, Green DR. Analysis of DNA fragmentation using agarose gel electrophoresis. *Cold Spring Harb Protoc*; 2006.
26. Bortner CD, Oldenburg NBE, Cidlowski JA. The role of DNA fragmentation in apoptosis. *Trends Cell Biol*. 1995;5:21.
27. Franken NA, Rodermond HM, Stap J, Haveman J, van Bree C. Clonogenic assay of cells *in vitro*. *Nat Protoc*. 2006;1(5): 2315-9.
28. Balunas MJ, Su B, Brueggemeier RW, Kinghorn AD. Xanthones from the botanical dietary supplement mangosteen (*Garcinia mangostana*) with aromatase inhibitory activity. *J Nat Prod*. 2008;71(7): 1161–6.

29. Akao Y, Nakagawa Y, linuma M, Nozawa Y. Anti-cancer effects of xanthenes from pericarps of mangosteen. *Int J Mol Sci.* 2008;9(3):355–70.
30. Pedraza-Chaverri J, Cardenas-Rodriguez N, Orozco-Ibarra M, Pérez-Rojas JM. Medicinal properties of mangosteen (*Garcinia mangostana*) *Food Chem Toxicol.* 2008;46(10):3227–39.
31. Hung SH, Shen KH, Wu CH, Liu CL, Shih YW. Alpha-mangostin suppresses PC-3 human prostate carcinoma cell metastasis by inhibiting matrix metalloproteinase-2/9 and urokinase-plasminogen expression through the JNK signaling pathway. *J Agr Food Chem.* 2009;57(4):1291–8.
32. Nakagawa Y, linuma M, Naoe T, Nozawa Y, Akao Y. Characterized mechanism of α -mangostin-induced cell death: Caspase-independent apoptosis with release of endonuclease-G from mitochondria and increased miR-143 expression in human colorectal cancer DLD-1 cells. *Bioorg. Med Chem.* 2007;16:5620–8.
33. Nakatani K, Nakahata N, Arakawa T, Yasuda H, Ohizumi Y. Inhibition of cyclooxygenase and prostaglandin E2 synthesis by gamma-mangostin, a xanthone derivative in mangosteen, in C6 rat glioma cells. *Biochem Pharmacol.* 2004;63:73–9.
34. Gopalakrishnan C, Shankaranarayanan D, Kameswaran L, Nazimudeen SK. Effect of mangostin, a xanthone from *Guarcinia mangostana* Linn. in immunopathological and inflammatory reactions. *Ind J Exp Biol.* 1980;18:843–6.
35. Akao Y, Nakagawa Y, M. linuma, and Y. Nozawa, Anticancer effects of xanthenes from pericarps of mangosteen, *Int J Mol Sci.* 2008;9(3):355–70.
36. Matsumoto K, Akao Y, Ohguchi K, Ito T, Tanaka T, linuma M, et al. Xanthenes induce cell-cycle arrest and apoptosis in human colon cancer DLD-1 cells. *Bioorg. Med Chem.* 2005;13:6064–9.
37. Watanapokasin R, Jarinthan F, Jerusalmi A, Suksamrarn S, Nakamura Y, Suksee S, et al. Potential of xanthenes from tropical fruit mangosteen as anti-cancer agents: caspase-dependent apoptosis induction *in vitro* and in mice. *Appl Biochem Biotech.* 2010;162(4):1080–94.
38. Balunas MJ, Su B, Brueggemeier RW, Kinghorn AD. Xanthenes from the botanical dietary supplement mangosteen (*Garcinia mangostana*) with aromatase inhibitory activity. *J Nat Prod.* 2008;71(7):1161–6.
39. Kantarjian H, Thomas D, O'Brien S, et al. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. *Cancer.* 2004;101(12):2788-801.
40. Bonadonna G, Valagussa P, Moliterni A, Zambetti M, Brambilla C. Adjuvant cyclophosphamide, methotrexate and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. *N Engl J Med.* 1995;332(14):901-6.
41. Fuchs N, Bielack SS, Epler D, Bieling P, Delling G, Köhrholz D, et al. Long-term results of the co-operative German-Austrian-Swiss osteosarcoma study group's protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs. *Ann Oncol.* 1998;9(8):893–9.
42. Ferreri AJM, Reni M, Dell'Oro S, Ciceri F, Bernardi M, Camba L, et al. Combined treatment with high-dose methotrexate, vincristine and procarbazine, without intrathecal chemotherapy, followed by consolidation radiotherapy for primary central nervous system lymphoma in immunocompetent patients. *Oncology.* 2001;60(2):134–40.
43. Guardiola E, Peyrade F, Chaigneau L, Cupissol D, Tchiknavorian X, Bompas E, et al. Results of a randomised phase II study comparing docetaxel with methotrexate in patients with recurrent head and neck cancer. *Eur J Cancer.* 2004;40(14):2071–6.
44. Osborn MJ, Freeman M, Huennekens FM. Inhibition of dihydrofolate reductase by aminopterin and amethopterin. *Proc Soc Exp Biol Med.* 1958;97(2):429–31.
45. Johnson JM, Meiering EM, Wright JE, Pardo J, Rosowsky A, Wagner G. NMR solution structure of the antitumor compound PT523 and NADPH in the ternary complex with human dihydrofolate reductase. *Biochem.* 1997;36(15):4399–411.
46. Paul M, Hemshekha M, Thushara RM, Sundaram MS, Naveen Kumar SK, Naveen S, et al. Methotrexate

promotes platelet apoptosis via JNK-mediated mitochondrial damage: alleviation by N-acetylcysteine and N-acetylcysteine amide. PLoS One. 2015;10(6):e0127558.

47. Sykes SM, Mellert HS, Holbert MA, Li K, Marmorstein R, Lane WS, McMahon SB. Acetylation of the DNA-binding domain regulates apoptosis induction. Mol Cell. 2006;24(6):841-51.

© 2020 Kirthanashri et al.; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peer-review history:

*The peer review history for this paper can be accessed here:
<http://www.sdiarticle4.com/review-history/57931>*